Fairvalue-Calculator Fairvalue-Calculator
EN DE

hVIVO plc (OPORF) Fair Value & Analysis

Healthcare · US · Market cap $75.4M

Price$0.1096
Fair Value$0.1100
Upside+0.4%
Quality95/100
Evidence: Low Range $0.0900 – $0.1400

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

hVIVO plc (OPORF) currently trades at $0.1096, while our model-based Fair Value estimate is $0.1100 — implying the stock looks roughly 0.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and c…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -54% Danaher Corporation (DHR) -54% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -52%

Frequently asked questions

Is hVIVO plc (OPORF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.1100 versus a price of $0.1096 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of OPORF?
Our 21-model fair value for hVIVO plc is $0.1100 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1096.
What is the quality score of OPORF?
hVIVO plc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.